Project Grant R44TR005328
Award Date
8/1/24
Completion Date
5/31/26
Dollars Obligated
$1.1M
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Mountain View, CA 94043, USA
Similar Awards
This Project Grant award of $324,998 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop novel lipid nanoparticle (LNP) delivery vehicles capable of efficiently transporting mRNA encoding telomerase (TERT) to target progenitor cell types. The awardee, Rejuvenation Technologies Inc. (RTI), seeks to expand the utility of their TERT mRNA biologic and LNP delivery platform by adding progenitor...
The National Center for Advancing Translational Sciences (NCATS), under the federal CFDA Program 93.350, awarded a $1,077,369 Project Grant to Captis Diagnostics Inc. to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid, efficient, and cost-effective isolation of extracellular vesicles (EVs) from non-invasive bodily fluids. The key objectives are to further optimize the LNP technology for EV enrichment from plasma, serum, urine, and saliva (Aim 1), and to...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
This $300,000 Project Grant was awarded on April 9, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports Optimeos Life Sciences, Inc., a biotechnology company, in developing an off-the-shelf, in situ chimeric antigen receptor regulatory T cell (CAR-Treg) therapy for treating transplant rejection. The project aims to overcome limitations of current ex vivo CAR-Treg therapies by...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,274,993 to Epicypher, Inc. to develop a new genomic technology called Reverse Transcribe & Tagmentation (RT & TAG) for the analysis of chromatin-associated RNAs (CARNAs) and nascent transcripts.
The key products and services to be delivered under this award include:
Optimizing RT & TAG to enable high-throughput characterization of polyadenylated CARNAs (Aim 1)
Extending RT...
The National Center for Advancing Translational Sciences (NCATS) awarded a $349,171 Project Grant (CFDA 93.350) to Cellchorus Inc. to develop LF-TIMING, an integrated computer vision system for label-free, high-throughput analysis of cell-cell interactions. The project aims to create advanced AI-driven software capable of accurately detecting, segmenting, classifying, and tracking individual cells in phase-contrast video recordings without the need for fluorescent labeling. This will free up...
This $644,864 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports preclinical studies by Ridgeline Therapeutics LLC, a Houston-based biotech company, to evaluate the efficacy of their lead compound RT-002 in preventing and reversing disuse-induced muscle atrophy in aging rat models. Specifically, the project aims to determine if RT-002 treatment can mitigate the loss of muscle mass and strength during muscle disuse, as well as improve the...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
This $700,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of next-generation RNAi (RNA interference) therapeutics and an in vivo model to evaluate their efficacy and biodistribution. The award aims to establish a pipeline to rapidly test new RNAi-based biological drugs coupled with various delivery platforms, including peptide-based, aptamer-based, and...